NTY Stock Overview
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Nabriva Therapeutics plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.39 |
52 Week High | US$8.50 |
52 Week Low | US$0.26 |
Beta | 1.55 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | -82.18% |
3 Year Change | -98.92% |
5 Year Change | -99.86% |
Change since IPO | -99.92% |
Recent News & Updates
Recent updates
Shareholder Returns
NTY | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | 3.0% | 1.3% |
1Y | -82.2% | -25.6% | 6.4% |
Return vs Industry: NTY underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: NTY underperformed the German Market which returned 5.9% over the past year.
Price Volatility
NTY volatility | |
---|---|
NTY Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 6.2% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NTY has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NTY's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 39 | J. Naftzger | https://www.nabriva.com |
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections.
Nabriva Therapeutics plc Fundamentals Summary
NTY fundamental statistics | |
---|---|
Market cap | €4.65m |
Earnings (TTM) | -€51.90m |
Revenue (TTM) | €33.52m |
0.1x
P/S Ratio-0.1x
P/E RatioIs NTY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NTY income statement (TTM) | |
---|---|
Revenue | US$36.94m |
Cost of Revenue | US$47.16m |
Gross Profit | -US$10.23m |
Other Expenses | US$46.96m |
Earnings | -US$57.18m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -17.86 |
Gross Margin | -27.69% |
Net Profit Margin | -154.83% |
Debt/Equity Ratio | 158.5% |
How did NTY perform over the long term?
See historical performance and comparison